Tolvaptan: a new tool for the effective treatment of hyponatremia in psychotic disorders

作者：Josiassen Richard C^*; Curtis Jessica; Filmyer Dawn M; Audino Brett; Skuban Nina; Shaughnessy Rita A

来源：Expert Opinion on Pharmacotherapy, 2010, 11(4): 637-648.

DOI：10.1517/14656561003610656

• hyponatremia
• osmotic demyelination
• psychogenic polydipsia
• SAMSCA
• schizophrenia
• syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
• tolvaptan (OPC-41061)
• vasopressin V-2-receptor antagonist
• water intoxication

Areas covered in the review: This review provides an overview of the existing literature on prevalence rates and risk factors associated with hyponatremia in psychotic patients (1923 - present). Tolvaptan is discussed as a potential advance in the treatment of hyponatremia in patients with psychotic disorders, and preliminary data are reviewed.
What the reader will gain: The reader will gain an appreciation of the prevalence of hyponatremia among psychotic individuals, an understanding of the distinctions between acute and chronic hyponatremia in this population, and awareness that effective treatments are becoming available.
Take home message: A modest literature exists regarding prevalence rates and risk factors associated with hyponatremia in psychotic populations. Hyponatremia is common and serious enough to merit clinical concern. Perhaps, now that tolvaptan has been FDA-approved, progress will accelerate and new insights will develop that begin to bring relief from this medical comorbidity among psychotic patients.

• 出版日期2010-3